OncoMatch/Clinical Trials/NCT05098132
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers
Is NCT05098132 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including STK-012 and pembrolizumab for advanced solid tumor.
Treatment: STK-012 · pembrolizumab · pemetrexed · carboplatin — This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of care (SoC) pembrolizumab, pemetrexed, and carboplatin versus SoC, in patients with first line, PD-L1 negative, non-squamous, non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Small Cell Lung Cancer
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) negative (tps <1%)
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage IV, IIIB, IIIC
Prior therapy
Cannot have received: immune checkpoint inhibitor
Prior immune checkpoint inhibitor (anti-PD[L]1 and/or anti-CTLA-4) treatment
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Arizona Cancer Center · Tucson, Arizona
- Beverly Hills Cancer Center · Beverly Hills, California
- Providence Medical Foundation · Fullerton, California
- UC San Diego Moores Cancer Center · La Jolla, California
- Hoag Memorial Hospital Presbyterian · Newport Beach, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify